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Aldosterone/Renin Ratio Determines Peripheral and
Central Blood Pressure Values Over a Broad Range
Andreas Tomaschitz, MD,* Winfried Maerz, MD,† Stefan Pilz, MD,* Eberhard Ritz, MD,‡
Hubert Scharnagl, PHD,† Wilfried Renner, PHD,† Bernhard O. Boehm, MD,§
Astrid Fahrleitner-Pammer, MD,* Gisela Weihrauch, MSC,† Harald Dobnig, MD*
Graz, Austria; and Heidelberg, Ulm, and Eppelheim, Germany
Objectives With the present analysis we intended to investigate the magnitude of the effect of relative aldosterone excess
in predicting peripheral as well as aortic blood pressure levels in a well-characterized cohort of patients undergo-
ing coronary angiography.
Background The discussion on the relationship between aldosterone concentration and blood pressure has recently gone be-
yond the role of primary aldosteronism in the genesis of arterial hypertension.
Methods Plasma aldosterone (pg/ml) and plasma renin concentration (pg/ml) were determined in 3,056 Caucasian pa-
tients (age 62.5  11 years; 31.9% women) scheduled for coronary angiography in a single tertiary care center.
We formed sex-specific deciles (D) according to plasma aldosterone/renin concentration ratio (ARR) (pg/ml/pg/ml).
Results Mean peripheral systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the entire cohort were 141
 24 mm Hg and 81  11 mm Hg, respectively. Mean ARR was 10.2  15.7 in men and 14.4  19.9 in
women (p  0.0001). Median SBP and aortic SBP increased steadily and significantly from ARR D1 (126.8 mm
Hg and 130.0 mm Hg, respectively) to D10 (151.0 mm Hg and 149.6 mm Hg, respectively; p  0.0001 for
both) after multivariate adjustment for age, sex, body mass index, renal function, antihypertensive medications,
and various parameters potentially influencing BP. Adjusted median DBP and aortic DBP also increased signifi-
cantly from 74.3 mm Hg and 66.5 mm Hg (D1) to 86.9 mm Hg and 76.7 mm Hg, respectively (D10) (p  0.001
for both). In a multivariate stepwise regression model, ARR emerged as the second most significant indepen-
dent predictor (after age) of mean SBP and as the most important predictor of mean DBP in this patient cohort.
Conclusions Our results: 1) underline that the ARR affects BP well below a cutoff used for screening for primary aldosteron-
ism; and 2) illustrate the importance of the ARR in modulating BP over a much wider range than is currently
appreciated. (J Am Coll Cardiol 2010;55:2171–80) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.032H
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aldosterone plays a key role in homeostatic control and
aintenance of blood pressure (BP) by regulation of extra-
ellular volume, vascular tone, and cardiac output.
Recent evidence has been interpreted to suggest that
ncreased aldosterone concentrations might be a more com-
on cause of elevated BP than previously thought. It has
een claimed that approximately 10% to 23% of patients
ith resistant hypertension and 2% to 13% of unselected
ypertensive patients have primary aldosteronism (1–3).
rom the *Division of Endocrinology and Nuclear Medicine, Department of Internal
edicine, and the †Clinical Institute of Medical and Chemical Laboratory Diagnos-
ics, Medical University of Graz, Graz, Austria; ‡Department of Internal Medicine,
eidelberg University, Heidelberg, Germany; §Division of Endocrinology and
iabetes, Department of Internal Medicine, University of Ulm, Ulm, Germany; and
he Synlab Center of Laboratory Diagnostics Heidelberg, Eppelheim, Germany. The
Udwigshafen RIsk and Cardiovascular Health Study has received unrestricted grants
rom Sanofi-Aventis, Roche, Dade Behring, and AstraZeneca.e
Manuscript received July 14, 2009; revised manuscript received October 30, 2009,
ccepted January 6, 2010.owever, the true prevalence of primary aldosteronism in
he setting of arterial hypertension has been the subject of
ontroversy (4–6).
See page 2181
There is an ongoing discussion whether these cases are
rue primary aldosteronism or the upper end of a continuum
xceeding an arbitrary threshold beyond which the diagnosis
f primary aldosteronism is made (5). Definite support for a
ajor role of the renin-angiotensin-aldosterone system in
he modulation of BP is the observation that two-thirds of
atients with refractory hypertension have a low renin status
nd can be treated effectively with an aldosterone antagonist
7). Numerous patients who have an elevated aldosterone/
enin concentration ratio (ARR) but not necessarily primary
ldosteronism might thus respond to blockade of the min-
ralocorticoid receptor.
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motensive individuals the plasma
aldosterone concentration (PAC)
is predictive for the subsequent
development of sustained hyper-
tension (8). Recently, Meneton et
al. (9) showed that in addition to
high plasma aldosterone low renin
levels precede the occurrence of
hypertension in middle-aged Cau-
casians. Moreover, a significant
positive association between ARR
and both risk and progression of
incident hypertension was re-
ported in normotensive subjects
(10). In a community-based sam-
ple a recent study further found a
positive correlation between the
ARR and various measures of ar-
terial stiffness (11). Toward this,
the ARR was positively associated
with pulse wave velocity in young
normotensive healthy adults, indi-
ating that relative aldosterone excess might affect arterial
emodeling and precede BP rise as a result of increased vascular
tiffness (12). Furthermore, Lim et al. (13) demonstrated a
orrelation between the ARR and exercise, office, and 24-h
mbulatory BP in 119 individuals adverting to a reduced
eripheral vascular compliance due to inappropriate aldoste-
one activity.
Low-renin essential hypertension and idiopathic hyper-
ldosteronism were proposed to represent 2 ends of a
ontinuum with a relative excess of aldosterone for a given
evel of renin (14,15). Important limitations in our under-
tanding include the difficulties of identifying a renin level as
low” and of comprehending the mechanisms that drive the
ctivation of the adrenal or extra-adrenal renin-angiotensin-
ldosterone system. At present, the relative importance for
drenal aldosterone production of circulating angiotensin II
oncentrations or other factors remains elusive (16). Finally,
here is currently no agreement on the true cutoff value that
uggests a diagnosis of primary aldosteronism.
The aim of the present study in a large cross-sectional
ohort of patients was to evaluate the impact of a relative
ldosterone excess, expressed by an elevated ARR on pe-
ipheral and central BP measurements in an effort to better
nderstand the role of the renin-angiotensin-aldosterone
ystem in determining the level of BP.
ethods
verview. The LUdwigshafen RIsk and Cardiovascular
ealth Study is an ongoing prospective cohort study of
aucasians, with and without cardiovascular disease at
aseline, investigating risk factors for coronary artery disease
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ANOVA  analysis of
variance
ARB  angiotensin-2
receptor blocker
ARR  aldosterone/renin
concentration ratio
BP  blood pressure
DBP  diastolic blood
pressure
NT-pBNP  N-terminal pro-
brain natriuretic peptide
PAC  plasma aldosterone
concentration
PRC  plasma renin
concentration
QU  quartile
SBP  systolic blood
pressurend mortality. The design and selection criteria of the oUdwigshafen RIsk and Cardiovascular Health Study have
een described previously (17). The study was approved by
he Ethics Committee at the A¨rztekammer Rheinland-
falz, Germany. Informed written consent was obtained
rom each of the participants.
All individuals enrolled underwent coronary angiography
n a tertiary care medical center and had to present in a
table clinical condition with the exception of acute coro-
ary artery syndrome. Individuals with major concomitant
oncardiovascular diseases or a history of malignancy were
xcluded.
tudy sample. After exclusion of 29 patients (0.95%)
aking mineralocorticoid receptor blocker or the diuretic
miloride and another 49 patients for whom aortic pressure
alues were not available, 3,056 individuals (mean age 62.5
ears; 31.9% women) remained in the analysis.
According to the JNC VII report (Seventh Report of the
oint National Committee for Prevention, Detection, Eval-
ation, and Treatment of Hypertension) (BP 140/90 mm
g and without antihypertensive medication), 173 (5.7%)
articipants were classified as normotensive, 2,219 (72.8%)
ere found to have elevated BP (140/90 mm Hg irrespec-
ive of antihypertensive medication), and 2,037 of this group
91.8%) took at least 1 antihypertensive drug (18). Resistant
ypertension, which was present in 32.8% of the subjects,
as defined as BP140/90 mm Hg or as130/80 mm Hg
n patients with diabetes or chronic kidney disease when 3
r more antihypertensive drugs, including a diuretic, were
aken and/or participants with normal BP required 4 or
ore antihypertensive medications (2,18). Secondary causes
f hypertension were considered on the basis of clinical
spects, blood electrolytes, free plasma catecholamines, cor-
isol, and cystatin C levels as a parameter of renal function.
ll patients were on a normal Western (sodium) diet.
ssessment of daily physical activity was based on a
patient-friendly” questionnaire that classified the average
aily life activities of study participants as follows: score 1
bed rest), score 2 (mostly supine), scores 3 to 5 (not very
ctive), scores 6 to 8 (normal domestic activities), scores 9 to
0 (physically demanding work or sports), score 11 (ex-
remely athletic) (17).
etermination of BP. Brachial artery pressure values were
easured with an automated oscillometric device (Omron
X4, Omron Health Care GmbH, Hamburg, Germany)
fter the patient had rested in the supine position for 10 min
17). At least 3 consecutive systolic blood pressure (SBP)
nd diastolic blood pressure (DBP) measurements were
aken with a minimum interval of 30 s. Finally, only
easurements conforming to the reproducibility criteria
ere entered into the database.
In addition, aortic pressure values (systolic and diastolic
ortic pressure) were measured invasively during coronary
ngiography/cardiac catheterization.
iomarker selection and clinical covariates. The stan-
ard laboratory methods used have been described previ-
usly (17). After an overnight fast, venous blood was
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May 11, 2010:2171–80 Aldosterone/Renin Ratio and BPampled in the morning before coronary angiography be-
ween 8:00 AM and 11:00 AM, with the participants in supine
osition for 5 to 10 min before phlebotomy.
We measured 9 biomarkers (PAC, plasma renin con-
entration [PRC], angiotensin 2, C-reactive protein,
ystatin C, plasma norepinephrine, plasminogen activator
nhibitor-1 antigens, plasma cortisol, and N-terminal
ro-brain natriuretic peptide [NT-pBNP]) representing
ey systems implicated in various pathogenetic aspects of
ypertension (19,20).
Plasma aldosterone concentration (pg/ml; conversion to
mol/l: pg/ml 2.774) was measured by radioimmunoassay
Active aldosterone/Diagnostic Systems Laboratories, Sin-
heim, Germany). Overall correlation between the radioim-
unoassay used and other commercially available assays
anges between 0.74 and 0.98 (21). The reference interval is
iven as 30 to 160 pg/ml (supine position).
Plasma renin concentration was determined by immuno-
adiometric assay (Active renin, Nichols Institute Diagnos-
ics, San Juan, Capistrano, California). The conversion
actor for PRC is based on a publication by Trenkel et al.
22) and is as follows: 1.67 U/ml ( mU/l) renin equals 1
g/ml ( ng/l) renin. The normal range is given as 4.2 to
5.6 pg/ml in upright position and as 3 to 28 pg/ml in
upine position.
With regard to the intra-assay and interassay coefficients of
ariation of these assays we refer to a previous publication (17).
The following additional covariates with an impact on BP
ere included in our analysis models: mean heart rate,
verage daily physical activity, history of myocardial infarc-
ion, current smoking status, and body mass index. Finally,
ral glucose tolerance test was performed in all subjects, and
ype 2 diabetes mellitus was diagnosed if plasma glucose was
1.25 g/l in the fasting state or 2.00 g/l 2 h after the
lucose load or if participants were already receiving oral
ntidiabetic drugs or insulin.
RR. The ARR was calculated as the PAC/PRC ratio
pg/ml/pg/ml) according to Trenkel et al. (22). An ARR
50 pg/ml/pg/ml was regarded as suggestive of primary
ldosteronism, yielding a sensitivity and specificity of ARR
f 89% and 96%, respectively (22). The ARR was modeled
s a continuous ratio (with log-transformed values).
tatistical analysis. Because of the significant ARR sex
ifference, baseline characteristics for clinical and biochem-
cal parameters are presented in sex-specific ARR quartiles
QUs). Categorical data are given as percentages, and
ontinuous variables are given as medians with interquartile
ange. Skewed variables were log-transformed to achieve
ormal distribution and rechecked for normality with the
olmogorov-Smirnov Test. Only these log-transformed
ariables were used in all of the following analyses.
Comparisons between ARR groups were performed with
ither the chi-square test for categorical data or analysis of
ariance (ANOVA) for continuous data. To better illustrate
ossible BP effects of ARR values over a broader range of hata, we also categorized patients into deciles of ARR and
gain adjusted for important clinical confounders.
One-way ANOVA followed by Bonferroni post hoc test
as used to compare mean systolic and diastolic peripheral
s well as aortic BP values across deciles of ARR. The basic
NOVA model was adjusted for age and sex. In a second
xtended model we additionally adjusted for the following
ovariates: body mass index, current smoking status, anti-
ypertensive medications (angiotensin-converting enzyme
ACE] inhibitors, angiotensin-2 receptor blockers (ARBs),
eta blockers, calcium-channel blockers, diuretics, and ni-
rates), aspirin/nonsteroidal antirheumatic agent treatment,
ype 2 diabetes mellitus, history of myocardial infarction,
ean heart rate, average daily physical activity, cystatin C,
-reactive protein, plasma norepinephrine, plasminogen
ctivator inhibitor-1 antigens, plasma cortisol, and NT-
BNP levels.
Overall influence of a specific antihypertensive medica-
ion on ARR was calculated by 1-way ANOVA adjusted for
ge, sex, body mass index, use of other specific antihyper-
ensive drugs, use of aspirin/nonsteroidal antirheumatic
gent, SBP, sodium/potassium concentrations, and the
ther aforementioned risk factors and biomarkers.
Differences in mean PAC, PRC, angiotensin 2, plasma
ortisol, norepinephrine, and NT-pBNP levels across sex-
pecific ARR deciles were calculated by multivariate ad-
usted 1-way ANOVA. Finally, multivariable stepwise re-
ression analysis (backward elimination) was performed to
dentify important predictors of BP.
A 2-sided p value of 0.05 was considered statistically
ignificant. Statistical analysis was performed with SPSS
oftware version 16.0 (SPSS, Inc., Chicago, Illinois).
esults
linical characteristics, relevant risk factors for hypertension,
nd biochemical markers are presented in Tables 1 and 2
ccording to sex-specific ARR QUs of the entire patient
ohort.
Overall, 98 participants (3.2% of the entire cohort, and
.4% of the hypertensive subjects) demonstrated an ARR
50 pg/ml/pg/ml (accounting for 12.8% of patients in
RR QU4), a threshold value above which a screening test
or primary aldosteronism was considered positive according
o a study using the same renin assay system as in the
resent study (22). The PAC doubled from QU1 to QU4,
hereas PRC increased by a factor of 10 from QU4 to QU1.
oth peripheral median sBP and dBP increased by 14.7 mm
g and 8.3 mm Hg with increasing QUs of ARR. Patients
n the lowest ARR QU1 had a higher prevalence of
omorbidities (as expressed by a higher Charlson comorbid-
ty index), presence of cardiovascular disease, and type 2
iabetes mellitus and belonged on average to higher New
ork Heart Association functional classes than patients in
ther QUs. Patients in the high-renin ARR QU1 had
igher angiotensin 2, NT-pBNP, and plasma norepineph-
r
w
b
l
a
a
r
s
w
s
w
a
A
h
i
d
c
d
a
E
s
B
V
s
o
h
( SD)
n PAC 
2174 Tomaschitz et al. JACC Vol. 55, No. 19, 2010
Aldosterone/Renin Ratio and BP May 11, 2010:2171–80ine and slightly lower plasma cortisol concentrations,
hereas serum electrolytes were only marginally different
etween the respective groups.
In an attempt to better illustrate the effects of aldosterone
evels and ARR on BP indexes, sex-adjusted deciles of
ldosterone and ARR were formed comprising between 299
nd 309 patients in each decile (Figs. 1A and 1B). With
egard to aldosterone deciles, there were only small but
ignificant differences in both SBP and DBP values over a
ide range of different multivariate adjusted absolute aldo-
terone concentrations. When aldosterone concentration
aseline Characteristics According to Sex-Specific ARR QuartilesTable 1 Baseline Characteristics According to Sex-Specific AR
Quartile 1
(n  755)
Qua
(n 
ARR, pg/ml/pg/ml 1.47 (0.8–2.2) 4.52 (3.7
Mean age, yrs 64 (56–71) 62 (55
Female sex 29.7 3
Body mass index, kg/m2 27.4 (24.8–30.1) 27.0 (24
Daily physical activity
Below average 10.2
Average 74.6 7
Above average 13.0 1
Charlson comorbidity index 2 (1–3) 1 (0–
Cardiovascular history
Current smoking status 20.9 2
NYHA functional class
I 47.4 5
II 25.0 2
III 22.9 1
IV 4.6
Type 2 diabetes mellitus 42.7 3
History of myocardial infarction 53.6 4
Coronary artery disease (50%) 75.7 7
History of hypertension 58.7 5
Hypertension 69.4 6
Resistant hypertension 27.2 2
Severe hypertension 1.2
BP measurements, mm Hg
Peripheral systolic BP 133.0 (117.0–150.7) 137.5 (12
Peripheral diastolic BP 76.7 (69.7–83.5) 79.0 (72
Aortic systolic BP 130 (120–150) 140 (12
Aortic diastolic BP 70 (60–75) 70 (65
Medication use
Number of AHM 2 (2–3) 2 (1–
ACE inhibitors 75.1 5
ARB 6.6
Beta blockers 59.9 6
Calcium-channel blockers 15.4 1
Diuretics 44.0 2
Nitrates 32.3 3
Aspirin/NSAR 71.5 7
alues are given asmedian (interquartile range) or percentage, unless otherwise indicated. The p va
ystolic BP 140 mm Hg and/or diastolic BP 90 mm Hg irrespective of use of antihypertensive
r chronic kidney disease or participants with 3 or more antihypertensive drugs including a diur
ypertension: BP 160/100 mm Hg.
ACE  angiotensin-converting enzyme; AHM  mean number of antihypertensive medication
onsteroidal antirheumatic agents; NYHA  New York Heart Association functional classification;as expressed relative to renin levels, however, mean SBP rnd DBP values were progressively higher across increasing
RR deciles.
In Table 3, 2 different models illustrate the effects of a
igher ARR on mean peripheral and aortic BP values. The
nclusion of various clinical and functional data as well as
ata on various medications influencing BP did not appre-
iably alter the overall correlations. The absolute mean
ifference in peripheral SBP and DBP between ARR D1
nd D10 was 24.2 mm Hg and 12.6 mm Hg, respectively.
xclusion of the 98 patients with an ARR 50 yielded a
imilar difference of 21.8 mm Hg and 11.6 mm Hg,
artiles
Quartile 3
(n  769)
Quartile 4
(n  767) p Value
8.89 (7.4–10.6) 21.21 (16.1–34.6) 0.001
63 (55–69) 63 (56–69) 0.199
30.0 30.2 0.818
6) 27.0 (24.9–29.4) 27.0 (24.8–29.6) 0.409
0.001
5.3 4.7
67.2 74.3
25.0 22.6
1 (0–2) 1 (0–2) 0.001
19.1 16.8 0.013
0.001
52.5 55.5
32.0 30.4
13.7 12.3
1.8 1.8
24.8 27.9 0.001
33.0 32.2 0.001
62.7 61.5 0.001
54.0 64.8 0.037
72.4 81.0 0.001
21.7 24.6 0.360
4.2 7.8 0.001
3.0) 141.7 (127.3–157.5) 147.7 (131.7–165.3) 0.001
3) 82.0 (74.7–89.3) 85.0 (78.0–92.5) 0.001
) 140 (125–160) 150 (130–170) 0.001
75 (65–80) 75 (70–80) 0.001
2 (1–3) 2 (1–3) 0.001
42.8 40.8 0.001
3.3 3.5 0.002
61.1 68.2 0.003
16.0 18.1 0.066
20.8 19.2 0.001
31.3 32.2 0.892
70.4 68.8 0.071
er to unadjusted comparisons. Blood pressure (BP) categories are defined as follows: hypertension:
tion; resistant hypertension: BP 140/90 mm Hg or 130/80 mm Hg in patients with diabetes
participants with normal BP but requiring 4 or more antihypertensive medications; and severe
; ARB  angiotensin receptor blockers; ARR  aldosterone/renin concentration ratio; NSAR 
plasma aldosterone concentration.R Qu
rtile 2
765)
–5.4)
–70)
0.1
.5–29.
5.1
4.1
9.3
2)
2.7
5.0
9.9
2.3
2.7
1.4
3.5
0.6
5.8
8.4
1.8
3.5
2.6–15
.1–87.
5–160
–80)
3)
2.0
4.6
3.0
3.5
6.5
2.0
5.4
lues ref
medica
etic orespectively. A separate analysis included only patients
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total n  1713). Here, peripheral mean SBP and DBP
alues were higher by 19.5 mm Hg and 9.1 mm Hg,
espectively, between the lowest and highest ARR category
nd were very similar to the findings for the overall cohort.
dditional adjustments for serum sodium and potassium
oncentration in the respective models did not influence
hese results materially.
Figures 2A and 2B demonstrate that the absolute
oncentration of PAC does not add to the information
aseline Biochemical Parameters According to Sex-Specific ARR QTable 2 Baseline Biochemical Parameters According to Sex-Sp
Quartile 1
(n  755)
Quar
(n 
PAC, pg/ml 57.0 (35.0–97.0) 64.0 (42.
PRC, pg/ml 41.4 (23.4–88.2) 14.4 (9.0
Angiotensin-2, ng/l 30.0 (17.0–59.0) 21.0 (13.
Plasma cortisol, mg/l 21.4 (17.2–25.8) 21.1 (16.
NT-pBNP, ng/ml 415.0 (144.0–1240.0) 239.0 (95.
GFR, ml/min/1.73 m2 78.9 (66.2–90.6) 81.8 (70.
Cystatin C, mg/l 0.96 (0.85–1.16) 0.90 (0.7
CRP, mg/dl 0.64 (0.24–1.55) 0.41 (0.1
Plasma norepinephrine, ng/l 355.0 (240.5–503.5) 299.0 (216
PAI-1, U/ml 19.0 (10.0–37.0) 19.0 (10.
Serum sodium level, mmol/l 141.0 (139.0–143.0) 141.0 (140
Serum potassium level, mmol/l 4.2 (4.0–4.4) 4.2 (4.0
alues are given as median (interquartile range).
CRP  C-reactive protein; GFR  glomerular filtration rate based on Modification of Diet in Re
nhibitor; PRC  plasma renin concentration; other abbreviations as in Table 1.
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10
160
150
140
130
120
90
80
70
60
Peripheral blood pressure, mmHg
A
Plasma Aldosterone Concentration (Deciles)
* * * *
†
Figure 1 Mean Systolic and Diastolic BP Values According to D
D1 to D10: indicate sex-specific deciles of log-transformed plasma aldosterone co
mately 300 patients are included in each decile. Blood pressure (BP) values are g
body mass index, daily physical activity, mean heart rate, current smoking status,
(angiotensin-converting enzyme inhibitors, angiotensin 2 receptor blockers, beta bl
rheumatic agents treatment, serum potassium and sodium levels, C-reactive prote
plasma cortisol, and N-terminal pro brain natriuretic peptide levels. Mean systolic
and 4.8 mm Hg, respectively, and across ARR deciles by 24.2 and 12.6 mm Hg, rrovided by the ARR. For every given QU of absolute
AC, the median BP was higher by a similar degree with
ising ARR QU.
Patients were further categorized according to key indi-
ators of renal (QU of cystatin C) and cardiac (QU of
T-pBNP levels) function, and there was the same rela-
ionship between ARR and both SBP as well as DBP. A
imilarly strong association between ARR and mean BP
alues was found in a subgroup analysis of 959 diabetic
atients (data not shown).
lesARR Quartiles
Quartile 3
(n  769)
Quartile 4
(n  767) p Value
.0) 80.0 (52.0–121.0) 110.0 (76.0–157.0) 0.001
9.0 (5.4–13.2) 4.2 (3.0–7.2) 0.001
) 18.0 (12.0–28.0) 15.0 (10.0–24.0) 0.001
) 21.9 (17.6–26.2) 23.3 (18.9–27.8) 0.001
.7) 203.0 (82.2–547.2) 275.5 (104.7–726.2) 0.001
) 83.0 (71.3–93.4) 80.9 (70.9–92.2) 0.027
) 0.88 (0.79–1.01) 0.89 (0.79–1.02) 0.001
) 0.32 (0.04–0.81) 0.29 (0.06–0.72) 0.001
5.0) 298.0 (205.2–421.7) 298.5 (207.7–419.2) 0.001
) 18.0 (10.0–34.0) 19.0 (10.0–33.0) 0.076
3.0) 141.0 (140.0–143.0) 142.0 (140.0–143.0) 0.001
4.2 (4.0–4.4) 4.1 (4.0–4.3) 0.001
ease formula; NT-pBNP  N-terminal pro-brain natriuretic peptide; PAI  plasminogen activator
* *
* * *
* *
*
*
*
*
* *
* *
*
*
*
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10
B
Peripheral blood pressure, mmHg
Aldosterone-to-renin ratio  (Deciles)
s of PAC and ARR
ation (PAC) (A) and aldosterone/renin concentration ratio (ARR) (B). Approxi-
s mean (95% confidence interval). Model is multivariate adjusted for age, sex,
diabetes mellitus, history of myocardial infarction, antihypertensive medication
, calcium-channel blockers, diuretics, and nitrates), aspirin/nonsteroidal anti-
sma norepinephrine, cystatin C, plasminogen activator inhibitor-1 antigens,
astolic peripheral BP values increase significantly across deciles of PAC by 7.0
tively. †p  0.05;* p  0.001, compared with reference decile 1.uartiecific
tile 2
765)
0–102
–22.8)
0–36.0
8–25.6
2–728
1–93.0
9–1.05
2–1.01
.5–42
0–35.0
.0–14
–4.4)ecile
ncentr
iven a
type 2
ockers
in, pla
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Aldosterone/Renin Ratio and BP May 11, 2010:2171–80Univariate correlation coefficients were highly signifi-
ant for log PRC versus log angiotensin-2 (r  0.553,
 0.001), log PRC versus log PAC (r  0.236, p 
.001), and log angiotensin-2 versus log PAC (r  0.233,
 0.001). Again, exclusion of patients with ACE
nhibitors as well as diuretics yielded similar results for all
RR Deciles and Mean Peripheral and Central (Aortic) BP MeasureTable 3 ARR Deciles and Mean Peripheral and Central (Aortic)
ARR Peripheral Systolic BP Perip
Model 1
D1 0.71 (0.45–0.99) 128.2 (125.9–130.3) 75
D2 1.72 (1.47–2.01) 133.7 (131.2–135.8)* 76
D3 2.88 (2.48–3.24) 135.8 (133.4–138.0)* 78
D4 4.11 (3.70–4.76) 139.0 (136.8–141.2)* 80
D5 5.35 (4.82–6.30) 137.7 (135.2–140.0)* 79
D6 7.01 (6.40–8.49) 140.9 (138.7–143.5)* 80
D7 9.03 (8.38–10.93) 141.6 (139.0–143.9)* 81
D8 12.26 (11.00–14.32) 142.2 (140.0–144.9)* 82
D9 18.33 (15.67–21.30) 145.5 (142.9–147.9)* 83
D10 39.08 (29.14–56.78) 150.7 (147.9–153.1)* 86
Model 2
D1 0.71 (0.45–0.99) 126.8 (124.5–129.1) 74
D2 1.72 (1.47–2.01) 133.0 (130.6–135.2)* 76
D3 2.88 (2.48–3.24) 135.8 (133.7–138.0)* 78
D4 4.11 (3.70–4.76) 139.0 (136.8–141.3)* 80
D5 5.35 (4.82–6.30) 139.0 (136.5–141.3)* 80
D6 7.01 (6.40–8.49) 141.3 (139.0–143.5)* 80
D7 9.03 (8.38–10.93) 141.3 (139.0–143.5)* 81
D8 12.26 (11.00–14.32) 143.2 (140.9–145.5)* 82
D9 18.33 (15.67–21.30) 145.9 (143.5–148.3)* 84
D10 39.08 (29.14–56.78) 151.0 (148.6–153.5)* 86
lood pressure (mm Hg) is given as mean (95% confidence interval). D1 to D10: indicate deciles of
: additionally adjusted for body mass index, current smoking status, antihypertensive medication
reatment, type 2 diabetes mellitus, history of myocardial infarction, mean heart rate, daily physica
og serum sodium and potassium levels. *p  0.001, compared with D1 (reference).
Abbreviations as in Tables 1 and 2.
Figure 2 Mean Peripheral Systolic and Diastolic BP According
Higher ARRs are associated with higher systolic (A) and diastolic (B) BP values
independently of absolute plasma aldosterone values. Q  quartiles; other abbrevforementioned correlation analyses. In general, patients
aking diuretics had significantly higher PRC and PAC
evels resulting in overall lower ARR values. The 5 most
mportant predictors of log PAC in a multivariate ad-
usted model with the same confounders as in Figure 3
total R2 of 21.8) were plasma cortisol, PRC, age, plasma
ts After Adjustment for Important Confounderseasurements After Adjustment for Important Confounders
iastolic BP Aortic Systolic BP Aortic Diastolic BP
.1–76.4) 130.3 (127.6–133.0) 67.6 (66.4–68.9)
.2–77.4)* 134.6 (131.8–137.4)* 67.6 (66.4–69.0)*
.7–79.3)* 136.8 (134.0–139.6)* 69.3 (68.1–70.8)*
.9–81.3)* 141.3 (138.7–144.2)* 71.1 (69.8–72.4)*
.3–80.7)* 139.6 (136.8–142.6)* 71.3 (70.0–72.6)*
.8–82.2)* 142.2 (139.3–145.2)* 72.1 (70.8–73.4)*
.7–83.2)* 139.0 (136.5–141.9)* 71.8 (70.5–73.1)*
.7–83.2)* 141.6 (139.0–144.5)* 71.9 (70.6–73.3)*
.8–85.3)* 146.2 (143.5–149.3)* 74.6 (73.3–76.0)*
.1–87.7)* 150.7 (147.6–153.8)* 76.4 (75.0–78.0)*
.1–75.5) 130.0 (127.4–133.0) 66.5 (65.2–67.9)
.0–77.3)* 134.9 (132.1–137.7)* 67.5 (66.1–68.7)*
.9–79.3)* 136.1 (133.7–139.0)* 68.9 (67.6–70.3)*
.9–81.1)* 141.6 (138.7–144.2)* 71.1 (69.7–72.4)*
.9–81.3)* 140.3 (137.4–143.2)* 71.4 (70.1–72.8)*
.6–82.0)* 141.9 (139.0–144.9)* 72.3 (71.0–73.8)*
.7–83.0)* 138.0 (135.5–140.9)* 71.8 (70.3–73.1)*
.3–83.8)* 141.9 (139.0–144.9)* 72.6 (71.1–74.0)*
.0–85.5)* 145.9 (142.9–148.6)* 74.8 (73.5–76.2)*
.5–88.1)* 149.6 (146.2–152.4)* 76.7 (75.3–78.3)*
-transformed ARR with median and interquartile range. Model 1: adjusted for age and sex; Model
hibitors, ARB, beta-blockers, calcium-channel blockers, diuretics, and nitrates) and aspirin/NSAR
ty, log CRP, log plasma norepinephrine, log cystatin C, log PAI-1, log plasma cortisol, log NT-pBNP,
of ARR and PAC
as in Figure 1.menBP M
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May 11, 2010:2171–80 Aldosterone/Renin Ratio and BPorepinephrine levels, and SBP. Likewise, the 5 most impor-
ant predictors of log renin levels (total R2 value of 38.0) were
BP, NT-pBNP, ACE inhibitors, diuretics, and PAC (data
ot shown).
Stepwise multivariate linear regression analysis was per-
ormed to identify predictors of peripheral and central BP
Table 4). Age and ARR emerged as the strongest predic-
ors for peripheral and aortic SBP, whereas for DBP, ARR
as of greatest influence.
In Figure 3, relevant key elements of the renin-angiotensin-
ldosterone system are superimposed graphically, together with
hanges seen in peripheral SBP values. One can appreciate that
ncreasing ARR categories are accompanied by higher values of
AC and that marked increases in PRC are a major charac-
eristic of lower ARR categories. The concentrations for PRC
nd PAC as well as angiotensin 2 are given as multivariate
Figure 3
Peripheral Systolic BP Values and
Components of Relevant Key Elements
of the Renin-Angiotensin-Aldosterone System
The ARR deciles are sex-adjusted. Mean values for peripheral systolic BP,
plasma aldosterone, renin and angiotensin 2 levels are adjusted for below con-
founders. Data for ARR are given as median of log-transformed values. Analy-
sis of variance models for all parameters are p  0.001. For the purpose of
this graph PAC value is given as ng/dl. Analysis of variance models for PAC,
plasma renin concentration (PRC), and angiotensin 2 were adjusted for: age,
sex, body mass index, average daily physical activity, current smoking status,
type 2 diabetes mellitus, history of myocardial infarction, peripheral systolic
BP, mean heart rate, antihypertensive therapy, aspirin/nonsteroidal antirheu-
matic agent use, C-reactive protein, cystatin C, N-terminal pro brain natriuretic
peptide, plasma norepinephrine, plasma cortisol, plasminogen activator
inhibitor-1, serum sodium, and potassium levels. CI  confidence interval;
other abbreviations as in Figure 1.djusted absolute levels.
aiscussion
he results of this study demonstrate that, across a broad
ange of ARR values, inappropriately elevated aldosterone
evels exert a strong effect on BP values and constitute the
ost important and second-most important predictor of
BP and SBP, respectively. Because all patients underwent
oronary angiography we also had the opportunity to
easure central (aortic) BP indexes that reflect loading
onditions on the myocardium and perfusion pressures of
oronary arteries, renal arteries, and cerebral vasculature
etter than brachial BP. A similar relationship was found, as
ith peripheral BP, between ARR and central BP values.
he size of the study population allowed us to form multiple
ategories of ARR. The results clearly illustrated that
ultivariate Stepwise Regressionnalysis to Identify Predictors f BPTable 4 Mul variate S pwise RegressionAnalysis to Identify Predictors of BP
Variables Beta 95% CI p Value
Prediction of Systolic Peripheral BP (Total R2  0.276)*
Age 0.340 (0.002 to 0.003) 0.001
ARR 0.278 (0.034 to 0.044) 0.001
ACE inhibitors 0.121 (0.013 to 0.023) 0.001
Sex –0.103 (–0.022 to –0.011) 0.001
History of myocardial infarction –0.103 (–0.020 to –0.010) 0.001
Mean heart rate 0.099 (0.066 to 0.132) 0.001
Body mass index 0.092 (0.001 to 0.002) 0.001
Type 2 diabetes mellitus 0.090 (0.009 to 0.019) 0.001
Calcium-channel blockers 0.083 (0.010 to 0.023) 0.001
Plasma norepinephrine 0.077 (0.013 to 0.034) 0.001
Nitrates 0.059 (0.004 to 0.014) 0.001
CRP –0.055 (–0.008 to –0.002) 0.001
Serum sodium 0.051 (0.161 to 0.693) 0.002
NT-pBNP –0.050 (–0.010 to –0.001) 0.010
ARB 0.048 (0.006 to 0.028) 0.003
PAI-1 0.047 (–0.002 to 0.014) 0.006
Diuretics –0.044 (–0.013 to –0.002) 0.013
Prediction of Diastolic Peripheral BP (Total R2: 0.223)†
ARR 0.321 (0.034 to 0.042) 0.001
Mean heart rate 0.206 (0.146 to 0.203) 0.001
Sex –0.152 (–0.025 to –0.016) 0.001
Body mass index 0.142 (0.002 to 0.003) 0.001
Plasma norepinephrine 0.133 (0.026 to 0.043) 0.001
ACE inhibitors 0.125 (0.011 to 0.020) 0.001
CRP –0.100 (–0.010 to –0.005) 0.001
Age 0.090 (0 to 0.001) 0.001
PAI-1 0.068 (0.005 to 0.015) 0.001
History of myocardial infarction –0.066 (–0.013 to –0.004) 0.001
Diuretics –0.055 (–0.012 to 0.003) 0.002
NT-pBNP –0.053 (–0.009 to –0.001) 0.008
Current smoking status –0.048 (–0.013 to –0.002) 0.006
Serum sodium 0.036 (0.027 to 0.489) 0.029
eta indicates linear regression coefficient. *Continuous variables were log-transformed when
ndicated; variables excluded by the model: aspirin/NSAR, beta blockers, cystatin C, plasma
ortisol, daily physical activity, current smoking status, and serum potassium; Upper table: R2
ithout log ARR is 0.218. †Variables excluded by the model: ARB, beta blockers, aspirin/NSAR,
itrates, calcium-channel blockers, cystatin C, serum potassium, plasma cortisol, daily physical
2ctivity, and type 2 diabetes mellitus; Lower table: R without log ARR is 0.147.
CI  confidence interval; other abbreviations as in Tables 1 and 2.
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Aldosterone/Renin Ratio and BP May 11, 2010:2171–80ncreasingly higher ARR values across deciles are paralleled
y steadily and gradually higher values of peripheral mean
P, ranging from 127 to 151 mm Hg SBP and 74 to 87
m Hg DBP, respectively. These data provide evidence
hat higher ARR values are paralleled by continuously and
rogressively higher BP values across a range from a
igh-renin to a low-renin state. We emphasize that no
vidence of a BP plateau was found. With respect to the first
nd last ARR decile, however, the BP difference to the
djacent deciles was greater than for other interdecile BP
ifferences. A potential reason for the greater BP difference
etween ARR deciles 9 and 10 might be the inclusion of
ome patients with primary aldosteronism. At the lower end
f ARR categories, a potential reason might be inclusion of
atients whose (very) high renin and low aldosterone levels
ight reflect strong aldosterone and renin responses to
CE inhibition and low BP values. However, excluding all
atients who were taking ACE inhibitor and ARB treat-
ent from the analysis did not change the relation between
RR and BP values. Patients without ACE inhibition had
n average slightly lower BP levels, also suggesting that
atients with higher BP were more likely to receive an ACE
nhibitor.
At a given ARR, the level of absolute PAC was of
omparably smaller relevance to BP values, indicating that
atients at different absolute PAC concentrations could
odulate PRC in a similar way. A raised ARR, by contrast,
lso often went along with PAC levels in the normal range.
he multivariate adjusted relationship between PAC and
P was significant but could be markedly improved when
RC was included to form the ARR with PAC. Thus, an
ncrease in sodium and water retention, leading to a volume-
ependent BP increase and consequently increased renal
erfusion and tubular sodium load, seems to decrease PRC
t different individual levels of PAC. Patients with low renin
evels could be found in both “low” as well as “high” PAC
ategories, and overall the data indicate that PRC is a BP
feedback-sensor” and a better indicator of individual aldo-
terone sensitivity than absolute PAC itself. Of note is yet
nother finding showing that, irrespective of renal and
ardiac function (categories formed by cystatin C and
T-pBNP levels), the correlation between ARR and BP
as maintained at all stages but with the limitation that the
esults can only be generalized to patients belonging to
idney Disease Outcome Quality Initiative and New York
eart Association functional classes I to III, due to only a
ew patients belonging to higher categories. It seems im-
ortant in this context to stress that, regardless of whether
nadjusted or multivariate adjusted models for calculation of
he effects of ARR on BP were used, very similar relation-
hips could be obtained; this suggests that the association
etween relative mineralocorticoid excess and BP is impor-
ant. We cannot make a valid statement regarding effects of
RR on BP within a normotensive cohort, but an ARR–
BP relationship was evident over a range of ARR ratios aelow values of 80 mm Hg, indicating that such an effect is
t work and reaches well into the normotensive BP range.
Of note, at the lower end of the ARR categories, the
arked increase in PRC was paralleled by a rise in circu-
ating angiotensin 2 levels but not, however, by a corre-
ponding increase in PAC. There might be several expla-
ations for the 10-fold higher PRC of ARR decile 1
ompared with decile 10; these include an elevated sympa-
hetic outflow as well as numerous different systemic and
ntrarenal factors that often accompany severe illness (23).
n line with this explanation is the observation that patients
elonging to the high renin group also had higher plasma
orepinephrine levels compared with patients in higher
RR categories. It seems interesting that a significant
levation of renin leads to a respective rise in angiotensin 2
ut does not translate into increased PAC. We can exclude
ntihypertensive medications and cardiac or renal dysfunc-
ion as likely causes, because controlling for these did not
hange the relationship substantially. The data suggest that,
ith marked increases in PRC, the adrenal cortex becomes
ess responsive toward angiotensin 2 stimulation.
There is little knowledge on possible mechanisms leading
o a relative excess of aldosterone secretion. Regulation of
drenal aldosterone synthesis is complex and depends on a
ariety of intra- and extra-adrenal stimulatory and inhibi-
ory factors (24,25).
In animal models a modest increased expression of the
ldosterone synthase, the enzyme that catalyzes the last step
f aldosterone synthesis, makes BP more sensitive to salt
26). Therefore, an inherited increased aldosterone synthase
xpression might contribute to hypertension in humans
ith chronic dietary salt-loading independent of the renin-
ngiotensin system. Newton-Cheh et al. (10) recently re-
orted in more than 3,300 individuals from the Framing-
am cohort that ARR was heritable (h2  40) and that
enome-wide genotyping might further identify variants
hat influence ARR. It was also suggested that aldosterone
ecretion is increased due to higher sensitivity toward
ngiotensin 2. Data of the present study, however, argue
gainst that because with increasing ARR deciles not only
enin but also angiotensin 2 levels declined, thus suggesting
hat the negative feedback loop between aldosterone and
enin was intact. Whether aldosterone excess is primarily
ue to autonomous secretion or due to other stimulatory
actors must remain subject to future research. We noticed
significant increase of plasma cortisol across ARR catego-
ies, and patients belonging to the highest plasma cortisol
U had a multivariate adjusted PAC that was 61% above
hat of QU1 (p  0.001). Chronic adrenal stimulation by
drenal corticotropic hormone, also reflected by elevated
lasma cortisol levels, was implicated as playing a critical
ole in maintenance and modulation of aldosterone synthe-
is (27). Connell et al. (27) reported that chronically
levated plasma cortisol levels are able to alter ARR by
cting as an adrenal cortex growth factor, leading to adrenal
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ngiotensin-2.
tudy limitations and strengths. This study has some
imitations. Because our patient cohort was composed ex-
lusively of elderly Caucasian participants, generalization to
ther ethnicities and younger individuals is not possible.
he impact of various classes of antihypertensive medica-
ions on ARR in our cohort was presumably small, although
t might have interfered to some degree with the interpre-
ation of our results. Previous studies, however, proved that
RR is an effective screening tool even in patients receiving
ntihypertensive treatment (28,29). We only had a single
easurement of ARR and 3 to 5 BP measurements avail-
ble. Another limitation is that ARR was measured on a
andom and not on a standardized sodium diet. Finally, the
ross-sectional design of our observational study precludes
onclusions with respect to causality.
Strengths of the study include its large size and the high
egree of clinical and biochemical characterization of the
atients. We had multiple key pathological parameters at
and that could be included in multivariate models. Fur-
hermore, with respect to the measurement of renin and
ldosterone levels, there is great controversy on different
ssay techniques, laboratory conditions, and influence of
onfounding variables. We chose the direct determination
f PRC, an approach that provides advantages in compar-
son with more commonly used assays measuring plasma
enin activity (29). Plasma renin concentration exhibits
etter diagnostic accuracy, provides interlaboratory repro-
ucibility, requires fewer pre-analytical prerequisites, and is
nown to correlate well with plasma renin activity measured
y enzyme kinetic assays (22,29–31).
linical Implications and Conclusions
he results of the present study suggest that overproduction
f aldosterone and its associated effects on sodium and water
etention as well as alterations of vascular function and
tructure are a major determinant of peripheral and—so far
ot appreciated—central BP. Because aldosterone has been
hown to promote vascular reactivity, inflammation, oxida-
ive stress, tissue remodelling, and endothelial dysfunction,
t is plausible to assume that inappropriate aldosterone
oncentrations have implications far beyond BP (32). The
ssociation between BP and the ARR is evident even at
orderline hypertensive BP values, and implies that a
arying degree of relative hyperaldosteronism is common
mong hypertensive patients. One important consequence
f the present study might be that relative hyperaldosteron-
sm provides a rationale for wider use of mineralocorticoid
eceptor blockade, especially when other antihypertensive
rugs are insufficient for the control of BP. Finally, more
esearch is needed to better understand the mechanisms
ontrolling aldosterone secretion and to make mineralocor-
icoid blockade a safe treatment option.cknowledgments
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